Top

Current Obesity Reports

Published in:

01-09-2021 | Obesity | Metabolism (M Dalamaga, Section Editor)

Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence

Authors: Natalia Vallianou, Maria Dalamaga, Theodora Stratigou, Irene Karampela, Christina Tsigalou

Published in: Current Obesity Reports | Issue 3/2021

Abstract

Purpose of Review

In this review, we summarize current evidence on the association between antibiotics and the subsequent development of obesity through modulation of the gut microbiome. Particular emphasis is given on (i) animal and human studies and their limitations; (ii) the reservoir of antibiotics in animal feed, emerging antibiotic resistance, gut dysbiosis, and obesity; (iii) the role of infections, specifically viral infections, as a cause of obesity; and (iv) the potential therapeutic approaches other than antibiotics to modulate gut microbiome.

Recent Findings

Overall, the majority of animal studies and meta-analyses of human studies on the association between antibiotics and subsequent development of obesity are suggestive of a link between exposure to antibiotics, particularly early exposure in life, and the development of subsequent obesity as a result of alterations in the diversity of gut microbiota. The evidence is strong in animal models whereas evidence in humans is inconclusive requiring well-designed, long-term longitudinal studies to examine this association. Based on recent meta-analyses and epidemiologic studies in healthy children, factors, such as the administration of antibiotics during the first 6 months of life, repeated exposure to antibiotics for ≥ 3 courses, treatment with broad-spectrum antibiotics, and male gender have been associated with increased odds of overweight/obesity.

Early antibiotic exposure in animal models has shown that reductions in the population size of specific microbiota, such as Lactobacillus, Allobaculum, Rikenellaceae, and Candidatus Arthromitus, are related to subsequent adiposity. These data suggest that the loss of diversity of the gut microbiome, especially early in life, may have potential long-term detrimental effects on the adult host gut microbiome and metabolic health. Genetic, environmental, and age-related factors influence the gut microbiome throughout the lifetime. More large-scale, longer-term, longitudinal studies are needed to determine whether changes that occur in the microbiome after exposure to antibiotics, particularly early exposure, are causal of subsequent weight gain or consequent of weight gain in humans.

Summary

Further well-designed, large-scale RCTs in humans are required to evaluate the effects of administration of antibiotics, particularly early administration, and the subsequent development of overweight/obesity. Therapeutic interventions, such as bacteriophage treatment or the use of probiotics, especially genetically engineered ones, need to be evaluated in terms of prevention and management of obesity.

NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–42. https://doi.org/10.1016/S0140-6736(17)32129-3.CrossRef

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics; 2017–2018. p. 2020.

https://www.who.int/health-topics/obesity. Accessed on December 20, 2020

Nishtar S, Gluckman P, Armstrong T. Ending childhood obesity: a time for action. Lancet. 2016;387(10021):825–7. https://doi.org/10.1016/S0140-6736(16)00140-9.4.CrossRefPubMed

Tsigalou C, Stavropoulou E, Bezirtzoglou E. Current insights in microbiome shifts in Sjogren's syndrome and possible therapeutic interventions. Front Immunol. 2018;9:1106. https://doi.org/10.3389/fimmu.2018.01106.CrossRefPubMedPubMedCentral

Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36. https://doi.org/10.1042/BCJ20160510.CrossRefPubMed

Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, et al. Food components and dietary habits: keys for a healthy gut microbiota composition. Nutrients. 2019;11(10):2393. https://doi.org/10.3390/nu11102393.CrossRefPubMedCentral

Grivennikov S, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254–8. https://doi.org/10.1038/nature11465.CrossRefPubMedPubMedCentral

Rea D, Coppola G, Palma G, Barbieri A, Luciano A, del Prete P, et al. Microbiota effects on cancer: from risks to therapies. Oncotarget. 2018;9(25):17915–27. https://doi.org/10.18632/oncotarget.24681.CrossRefPubMedPubMedCentral

10.

Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12. https://doi.org/10.1038/nrc3610.CrossRefPubMedPubMedCentral

11.

Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014, 146(6):1534–1546.e3. https://doi.org/10.1053/j.gastro.2014.01.001.

12.

Vallianou NG, Tzortzatou-Stathopoulou F. Microbiota and cancer: an update. J Chemother. 2019;31(2):59–63. https://doi.org/10.1080/1120009X.2018.1541046.CrossRefPubMed

13.

Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. Curr Obes Rep. 2019;8(3):317–32. https://doi.org/10.1007/s13679-019-00352-2.CrossRefPubMed

14.

Rinninela E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasparrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. https://doi.org/10.3390/microorganisms7010014.CrossRef

15.

Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7. https://doi.org/10.1038/nature11053.CrossRefPubMedPubMedCentral

16.

Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4578–85.CrossRefPubMed

17.

Dominguez-Bello MG, Costello EK, Contreras M, Makris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971–5. https://doi.org/10.1073/pnas.1002601107.CrossRefPubMedPubMedCentral

18.

Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology. 2011;140(6):1713–9. https://doi.org/10.1053/j.gastro.2011.02.011.CrossRefPubMed

19.

Zeissig S, Blumberg RS. Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol. 2014;15(4):307–10. https://doi.org/10.1038/ni.2847.CrossRefPubMed

20.

Agace WW, McCoy KD. Regionalized development and maintenance of the intestinal adaptive immune landscape. Immunity. 2017;46(4):532–48. https://doi.org/10.1016/j.immuni.2017.04.004.CrossRefPubMed

21.

Vallianou NG, Geladari E, Kounatidis D. Microbiome and hypertension: where are we now? J Cardiovasc Med. 2020;21(2):83–8. https://doi.org/10.2459/JCM.0000000000000900.CrossRef

22.

•• Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, Prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr Obes Rep. 2020;9(3):179–92. https://doi.org/10.1007/s13679-020-00379-wIn this review, current evidence on gut microbiome and obesity, the role of probiotics, prebiotics, synbiotics, and postbiotics in obesity prevention and management and their main limitations, challenges, and controversies of their use are discussed.CrossRefPubMed

23.

• Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72. https://doi.org/10.2337/db06-1491In this study, authors have shown that the LPS-CD14 system is implicated in the development of diabetes and obesity in mice, and they have proposed that lowering plasma LPS levels could be useful in preventing metabolic disorders.CrossRefPubMed

24.

• Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med. 2016;22(7):713–22. https://doi.org/10.1038/nm.4142In this review, prenatal as well as postnatal factors that affect the shaping of the human gut microbiota and its interactions with the immune system are discussed.CrossRefPubMed

25.

Charbonneau MR, Blanton LV, DiGiulio DB, Relman DA, Lebrilla CB, Mills DA, et al. A microbial perspective of human developmental biology. Nature. 2016;535(7610):48–55. https://doi.org/10.1038/nature18845.CrossRefPubMedPubMedCentral

26.

Vallianou NG, Stratigou T, Tsagarakis S. Microbiome and diabetes: where are we now? Diabetes Res Clin Pract. 2018;146:111–8. https://doi.org/10.1016/j.diabres.2018.10.008.CrossRefPubMed

27.

Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439. https://doi.org/10.1126/science.1237439.CrossRefPubMedPubMedCentral

28.

Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23. https://doi.org/10.1073/pnas.0407076101.CrossRefPubMedPubMedCentral

29.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/nature05414.CrossRefPubMed

30.

Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213–23. https://doi.org/10.1016/j.chom.2008.02.015.CrossRefPubMedPubMedCentral

31.

Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23:859–68. https://doi.org/10.1038/nm.4358.CrossRefPubMed

32.

Parnell JL, Reimer RA. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Gut Microbes. 2012;3(1):29–34. https://doi.org/10.4161/gmic.19246.CrossRefPubMed

33.

Tims S, Derom C, Jonkers DM, Vlietinck R, Saris WH, Kleerebezel M, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J. 2013;7:707–17. https://doi.org/10.1038/ismej.2012.146.CrossRefPubMed

34.

Bansal T, Alaniz RC, Wood TK, Jayaraman A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc Natl Acad Sci U S A. 2010;107:228–33. https://doi.org/10.1073/pnas.0906112107.CrossRefPubMed

35.

Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18(1):190–5. https://doi.org/10.1038/oby.2009.167.CrossRefPubMed

36.

Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. Febbs Lett. 2014;588(22):4223–33. https://doi.org/10.1016/j.febslet.2014.09.039.CrossRef

37.

Sze MA, Schloss PD. Looking for a signal in the noise: revisiting obesity and the microbiome. mBio. 2016;7(4):e01018–6. https://doi.org/10.1128/mBio.01018-16.CrossRefPubMedPubMedCentral

38.

Fan Y, Pedersen O. Human gut microbiota in metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71. https://doi.org/10.1038/s41579-020-0433-9.CrossRefPubMed

39.

Klancic T, Reimer RA. Gut microbiota and obesity: Impact of antibiotics and prebiotics and potential for musculoskeletal health. J Sport Health Sci. 2020;9(2):110–8. https://doi.org/10.1016/j.jshs.2019.04.004.CrossRefPubMed

40.

Moran-Ramos S, Lopez-Contreras BE, Canizales-Quinteros S. Gut microbiota in obesity and metabolic abnormalities: a matter of composition or functionality? Arch Med Res. 2017;48(8):735–53. https://doi.org/10.1016/j.arcmed.2017.11.003.CrossRefPubMed

41.

Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, et al. Gut microbiota markers in obese adolescent and adult patients: age-dependent differential patterns. Front Microbiol. 2018;9:1210. https://doi.org/10.3389/fmicb.2018.01210.CrossRefPubMedPubMedCentral

42.

Joyce SA, Gahan C. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis. 2017;35(3):169–77. https://doi.org/10.1159/000450907.CrossRefPubMed

43.

Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17(5):662–71. https://doi.org/10.1016/j.chom.2015.03.005.CrossRefPubMedPubMedCentral

44.

Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21(9):793–8. https://doi.org/10.1136/gut.21.9.793.CrossRefPubMedPubMedCentral

45.

Canfora EE, Meex R, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–73. https://doi.org/10.1038/s41574-019-0156-z.CrossRefPubMed

46.

Blaak E, Canfora E, Theis S, Frost G, Groen A, Mithieux G, et al. Short chain fatty acids in human gut and metabolic health. Benefic Microbes. 2020;11(5):411–55. https://doi.org/10.3920/BM2020.0057.CrossRef

47.

Chambers E, Viardot A, Psichas A, Morrison D, Murphy K. Zac-Varghese, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744–54. https://doi.org/10.1136/gutjnl-2014-307913.CrossRefPubMed

48.

de la Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299(2):440–8. https://doi.org/10.1152/ajpgi.00098.2010.CrossRef

49.

Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–88. https://doi.org/10.4161/gmic.19625.CrossRefPubMedPubMedCentral

50.

Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol. 2000;12(1):20–6. https://doi.org/10.1016/s0952-7915(99)00046-1.CrossRefPubMed

51.

Shi H, Kokoeva MV, Inoue K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25. https://doi.org/10.1172/JCI28898.CrossRefPubMedPubMedCentral

52.

Belancic A. Gut microbiome dysbiosis and endotoxemia - additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes Med. 2020;20:100302. https://doi.org/10.1016/j.obmed.2020.100302.CrossRefPubMedPubMedCentral

53.

Shinde T, Hansbro PM, Sohal SS, Dingle P, Eri R, Stanley R. Microbiota modulating nutritional approaches to countering the effects of viral respiratory infections including SARS-CoV-2 through promoting metabolic and immune fitness with probiotics and plant bioactives. Microorganisms. 2020;8(6):921. https://doi.org/10.3390/microorganisms8060921.CrossRefPubMedCentral

54.

•• Ribeiro C, Silveira G, Candido E, Cardoso M, Carvalho C, Franco O. Effects of antibiotic treatment on gut microbiota and how to overcome its negative impacts on human health. ACS Infect Dis. 2020;6(10):2544–59. https://doi.org/10.1021/acsinfecdis.0c00036The authors analyze the significance of the development of newer antibiotics, which would not interfere severely with the gut microbiota and, thus, would not predispose the host to dysbiosis.CrossRefPubMed

55.

Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, et al. Association of adverse drug events with broad-spectrum antibiotic use in hospitalized patients: a single-center study. Intern Med. 2019;58(18):2621–5. https://doi.org/10.2169/internalmedicine.2603-18.CrossRefPubMedPubMedCentral

56.

Yoon MY, Yoon SS. Disruption of the gut ecosystem by antibiotics. Yonsei Med J. 2018;59(1):4–12. https://doi.org/10.3349/ymj.2018.59.1.4.CrossRefPubMed

57.

Caprio J, Rantz LA. Effects of terramycin on the bacterial flora of the bowel in man. AMA Arch Intern Med. 1950;86(5):649–57. https://doi.org/10.1001/archinte.1950.00230170002001.CrossRef

58.

Konstantinidis T, Tsigalou C, Karvelas A, Stavropoulou E, Voidarou C, Berirtzoglou E. Effects of antibiotics upon the gut microbiome: a review of the literature. Biomedicines. 2020;8(11):502. https://doi.org/10.3390/biomedicines8110502.CrossRefPubMedCentral

59.

Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: clostridium difficile infection and the threat of antibiotic resistance. Genes. 2015;6(4):1347–60. https://doi.org/10.3390/genes6041347.CrossRefPubMedPubMedCentral

60.

Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;373(3):287–8. https://doi.org/10.1056/NEJMc1506004.CrossRefPubMed

61.

Iizumi T, Battaglia T, Ruiz V, Perez G. Gut microbiome and antibiotics. Arch Med Res. 2017;48(8):727–34. https://doi.org/10.1016/j.arcmed.2017.11.004.CrossRefPubMed

62.

Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41. https://doi.org/10.1016/j.cell.2014.03.011.CrossRefPubMedPubMedCentral

63.

•• Cox LM, Blaser MA. Antibiotics in early life and obesity. Nat Rev Endocrinol. 2015;11(3):182–90. https://doi.org/10.1038/nrendo.2014.210The authors summarize the mechanisms by which the administration of antibiotics early in life, especially within the first 6 months, together with the repeated administration of antibiotics, may alter the gut microbiota, thus, leading to obesity. They focus on early life administration of antibiotics, as this period seems to be particularly vulnerable to metabolic outcomes.CrossRefPubMed

64.

Tsigalou C, Konstantinidis T, Stavropoulou E, Bezirtzoglou EE, Tsakris A. Potential elimination of human gut resistome by exploiting the benefits of functional foods. Front Microbiol. 2020;11:50. https://doi.org/10.3389/fmicb.2020.00050.CrossRefPubMedPubMedCentral

65.

Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4554–61. https://doi.org/10.1073/pnas.1000087107.CrossRefPubMed

66.

•• Leong K, Derraik J, Hofman P, Cutfield W. Antibiotics, gut microbiome and obesity. Clin Endocrinol. 2018;88(2):185–200. https://doi.org/10.1111/cen.13495The authors have made a detailed review on the association between the administration of antibiotics and its consequences in terms of alterations of the gut microbiome and the subsequent development of obesity.CrossRef

67.

Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA. PLoS Biol. 2008;6(11):e280. https://doi.org/10.1371/journal.pbio.0060280.CrossRefPubMedPubMedCentral

68.

Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. https://doi.org/10.1371/journal.pone.0009836.CrossRefPubMedPubMedCentral

69.

Perez-Cobas AE, Artacho A, Knecht H, Ferrus ML, Friedrichs A, Ott SJ, et al. Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One. 2013;8(11):e80201. https://doi.org/10.1371/journal.pone.0080201.CrossRefPubMedPubMedCentral

70.

Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014;165(1):23–9. https://doi.org/10.1016/j.jpeds.2014.01.010.CrossRefPubMedPubMedCentral

71.

Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60(4):824–31. https://doi.org/10.1016/j.jhep.2013.11.034.CrossRefPubMed

72.

Panda S, El Khader I, Casellas F, Vivancos JL, Cors MG, Santiago A, et al. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014;9(4):e95476. https://doi.org/10.1371/journal.pone.0095476.CrossRefPubMedPubMedCentral

73.

Stewardson AJ, Gaia N, Francois P, Malhotra-Kumar S, Delemont C, De Tejada BM, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin Microbiol Infect. 2015;21(4):344.e1–11. https://doi.org/10.1016/j.cmi.2014.11.016.CrossRef

74.

Mikkelsen KH, Frost M, Bahl MI, Licht TR, Jensen US, Rosenberg J, et al. Effect of antibiotics on gut microbiota, gut hormones and glucose metabolism. PLoS One. 2015;10(11):e0142352. https://doi.org/10.1371/journal.pone.0142352.CrossRefPubMedPubMedCentral

75.

Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Microbiol Infect. 2015;60(Suppl 2):S77–84. https://doi.org/10.1093/cid/civ137.CrossRef

76.

Lichtman JS, Ferreyra JA, Ng KM, Smits SA, Sonnenburg JL, Elias JE. Host-microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep. 2016;4(5):1049–61. https://doi.org/10.1016/j.celrep.2016.01.009.CrossRef

77.

Korpela K, Mutanen A, Salonen A, Savilahti E, De Vos W, Pakarinen MP. Intestinal microbiota signatures associated with histological liver steatosis in pediatric-onset intestinal failure. JPEN J Parenter Enteral Nutr. 2017;41(2):238–48. https://doi.org/10.1177/0148607115584388.CrossRefPubMed

78.

Lankelma JM, Cranendonk DR, Belzer C, De Vos A, De Vos W, Der Poll T, et al. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. Gut. 2017;66(9):1623–30. https://doi.org/10.1136/gutjnl-2016-312132.CrossRefPubMed

79.

Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Aline KH, Nielsen T, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255–65. https://doi.org/10.1038/s41564-018-0257-9.CrossRefPubMed

80.

Willmann M, Vehreschild M, Biehl LM, Vogel W, Dorfel D, Hamprecht A, et al. Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol. 2019;17(1):76. https://doi.org/10.1186/s12915-019-0692-y.CrossRefPubMedPubMedCentral

81.

Xu L, Surathu A, Raplee I, Chockalingam A, Stewart S, Walker L, et al. The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice. BMC Genomics. 2020;21(1):263. https://doi.org/10.1186/s12864-020-6665-2.CrossRefPubMedPubMedCentral

82.

•• Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. J Inf Secur. 2019;79(6):471–89. https://doi.org/10.1016/j.jinf.2019.10.008This is a systematic review on the effects of the administration of a plethora of antibiotics on the composition of the gut microbiota, highlighting that newer antibiotics or the administration of probiotics could have beneficial effects in the prevention of dysbiosis.CrossRef

83.

Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156(Pt 11):3216–23. https://doi.org/10.1099/mic.0.040618-0.CrossRefPubMed

84.

Isaac S, Scher JU, Djukovic A, Jimenez N, Littman DR, Abramson SB, et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother. 2017;72(1):128–36. https://doi.org/10.1093/jac/dkw383.CrossRefPubMed

85.

Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621–6. https://doi.org/10.1038/nature11400.CrossRefPubMedPubMedCentral

86.

Cox L, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158(4):705–21. https://doi.org/10.1016/j.cell.2014.05.052.CrossRefPubMedPubMedCentral

87.

Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979–84. https://doi.org/10.1073/pnas.0605374104.CrossRefPubMedPubMedCentral

88.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81. https://doi.org/10.2337/db07-1403.CrossRefPubMed

89.

Murphy EF, Cotter PD, Hogan A, O'Sullivan O, Joyce A, Fouhy F, et al. Divergent metabolic outcomes arising from targeted manipulations of the gut microbiota in diet-induced obesity. Gut. 2013;62(2):220–6. https://doi.org/10.1136/gutjnl-2011-300705.CrossRefPubMed

90.

Mahana D, Trend C, Kurtz Z, Boculich N, Battaglia T, Chung J, et al. Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet. Genome Med. 2016;8(1):48. https://doi.org/10.1186/s13073-016-0297-9.CrossRefPubMedPubMedCentral

91.

Rodrigues R, Greer R, Dong X, Dsouza K, Gurung M, Wu J, et al. Antibiotic-induced alterations in gut microbiota are associated with changes in glucose metabolism in healthy mice. Front Microbiol. 2017;8:2306. https://doi.org/10.3389/fmicb.2017.02306.CrossRefPubMedPubMedCentral

92.

Li R, Wang H, Shi Q, Wang N, Zhang Z, Xiong C, et al. Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice. PLoS One. 2017;12(7):e0181690. https://doi.org/10.1371/journal.pone.0181690.CrossRefPubMedPubMedCentral

93.

Zarrinpar A, Chaix A, Xu Z, Chang M, Marotz C, Saghatelian A, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat Commun. 2018;9(1):2872. https://doi.org/10.1038/s41467-018-05336-9.CrossRefPubMedPubMedCentral

94.

Dibner JJ, Richards JD. Antibiotic growth promoters in agriculture: history and mode of action. Poult Sci. 2005;84(4):634–43. https://doi.org/10.1093/ps/84.4.634.CrossRefPubMed

95.

Gaskins HR, Collier CT, Anderson DB. Antibiotics as growth promotants: mode of action. Anim Biotechnol. 2002;13(1):29–42. https://doi.org/10.1081/ABIO-120005768.CrossRefPubMed

96.

Mohammadkhah A, Simpson E, Patterson S, Ferguson J. Development of the gut microbiome in children, and lifetime implications for obesity and cardiometabolic disease. Children (Basel). 2018;5(12):160. https://doi.org/10.3390/children5120160.CrossRef

97.

Bliss E, Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol. 2018;19:900. https://doi.org/10.3389/fphys.201800900.CrossRef

98.

Butaye P, Devriese LA, Haesebrouck F. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin Microbiol Rev. 2003;16(2):175–88. https://doi.org/10.1128/cmr.16.2.175-188.2003.CrossRefPubMedPubMedCentral

99.

Gough E, Moodie E, Prendergast A, Johnson S, Humphrey J, Stoltzfus R, et al. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g2267. https://doi.org/10.1136/bmj.g2267.CrossRefPubMedPubMedCentral

100.

Shao X, Ding X, Wang B, Li L, An X, Yao Q, et al. Antibiotic exposure in early life increases risk of childhood obesity: a systematic review and meta-analysis. Front Endocrinol. 2017;8:170. https://doi.org/10.3389/fendo.2017.00170.CrossRef

101.

Wan S, Guo M, Zhang T, Chen Q, Wu M, Teng F, et al. Impact of exposure to antibiotics during pregnancy and infancy on childhood obesity: a systematic review and meta-analysis. Obesity. 2020;28(4):793–802. https://doi.org/10.1002/oby.22747.CrossRefPubMed

102.

Thuny F, Richet H, Casalta JP, Angelakis P, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One. 2010;5(2):e9074. https://doi.org/10.1371/journal.pone.0009074.CrossRefPubMedPubMedCentral

103.

Saiman L, Anstead M, Mayer-Hamblett N, Lands L, Kloster M, Hosevar-Trnka J, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707–15. https://doi.org/10.1001/jama.2010.563.CrossRefPubMed

104.

Ajslev TA, Andersen CS, Gamborg M, Sorensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes. 2011;35(4):522–9. https://doi.org/10.1038/ijo.2011.27.CrossRef

105.

Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 2011;11:37. https://doi.org/10.1186/1471-230X-11-37.CrossRefPubMedPubMedCentral

106.

Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. Int J Obes. 2013;37(1):16–23. https://doi.org/10.1038/ijo.2012.132.CrossRef

107.

Murphy R, Stewart AW, Braithwaite I, Beasly R, Hancox RJ, Mitchell EA, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes. 2014;38(8):1115–9. https://doi.org/10.1038/ijo.2013.218.CrossRef

108.

Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;68(11):1063–9. https://doi.org/10.1001/jamapediatrics.2014.1539.CrossRef

109.

Azad MB, Bridgman SL, Becker AB, Kojurskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes. 2014;38(10):1290–8. https://doi.org/10.1038/ijo.2014.119.CrossRef

110.

Angelakis E, Million M, Kankoe S, Lagier JC, Armougom F, Giorgi R. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother. 2014;58(6):3342–7. https://doi.org/10.1128/AAC.02437-14.CrossRefPubMedPubMedCentral

111.

Saari A, Virta LJ, Sankilampi U, Denkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015;135(4):617–26. https://doi.org/10.1542/peds.2014-3407.CrossRefPubMed

112.

Edmonson MB, Eikhoff JC. Weight gain and obesity in infants and young children exposed to prolonged antibiotic prophylaxis. JAMA Pediatr. 2017;171(2):150–6. https://doi.org/10.1001/jamapediatrics.2016.3349.CrossRefPubMed

113.

Scott FI, Horton DB, Mamtani R, Haynes K, Goldberg DS, Lee DY, et al. Administration of antibiotics to children before age 2 years increases risk for childhood obesity. Gastroenterology. 2016;151(1):120–129.e5. https://doi.org/10.1053/j.gastro.2016.03.006.CrossRefPubMed

114.

•• Li DK, Chen H, Ferber J, Odouli R. Infection and antibiotic use in infancy and risk of childhood obesity: a longitudinal birth cohort study. Lancet Diabetes Endocrinol. 2017;5(1):18–25. https://doi.org/10.1016/S2213-8587(16)30281-9In this longitudinal birth cohort study of 260, 556 individuals, infection, but not antibiotic use, during infancy was associated with risk of childhood obesity.CrossRefPubMed

115.

Stark CM, Susi A, Emerick J, Nylund CD. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68(1):62–9. https://doi.org/10.1136/gutjnl-2017-314971.CrossRefPubMed

116.

Kelly D, Kelly A, O’Dowd T, Hays CB. Antibiotic use in early childhood and risk of obesity: longitudinal analysis of a national cohort. World J Pediatr. 2019;15(4):390–7. https://doi.org/10.1007/s12519-018-00223-1.CrossRefPubMed

117.

Park YJ, Chang J, Lee G, Son JS, Park SM. Association of class number, cumulative exposure, and earlier initiation of antibiotics during the first two-years of life with subsequent childhood obesity. Metabolism. 2020;112:1543–8. https://doi.org/10.1016/j.metabol.2020.154348.CrossRef

118.

Chelimo C, Camargo CA, Morton S, Grant CC. Association of repeated antibiotic exposure up to age 4 years with body mass at age 4.5 years. JAMA Netw Open. 2020;3(1):e1917577. https://doi.org/10.1001/jamanetworkopen.2019.17577.CrossRefPubMedPubMedCentral

119.

Gerber JS, Bryan M, Ross RK, Daymont C, Parks EP, Locialo AR, et al. Antibiotic exposure during the first 6 months of life and weight gain during childhood. JAMA. 2016;315(12):1258–65. https://doi.org/10.1001/jama.2016.2395.CrossRefPubMed

120.

Cromwell GL. Why and how antibiotics are used in swine production. Anim Biotechnol. 2002;13(1):7–27. https://doi.org/10.1081/ABIO-120005767.CrossRefPubMed

121.

Castanon J. History of the use of antibiotic as growth promoters in European poultry feeds. Poult Sci. 2007;86(11):2466–71. https://doi.org/10.3382/ps.2007-00249.CrossRefPubMed

122.

Taleghani AH, Lim TT, Lin CH, Ericsson AC, Vo PH. Degradation of veterinary antibiotics in swine manure via anaerobic digestion. Bioengineering. 2020;7(4):123. https://doi.org/10.3390/bioengineering7040123.CrossRef

123.

Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–8. https://doi.org/10.1016/S1473-3099(15)00424-7.CrossRefPubMed

124.

Jess T, Morgen CS, Harpsoe MC, Sorensen T, Ajslev TA, Antvorskov JC, et al. Antibiotic use during pregnancy and childhood overweight: a population-based nationwide cohort study. Sci Rep. 2019;9(1):11528. https://doi.org/10.1038/s41598-019-48065-9.CrossRefPubMedPubMedCentral

125.

Dhuradhar NV. Infectobesity: obesity of infectious origin. J Nutr. 2001;131(10):2794S–7S. https://doi.org/10.1093/jn/131.10.2794S.CrossRef

126.

Atkinson RL. Viruses as an etiology of obesity. Mayo Clin Proc. 2007;82(10):1192–8.CrossRefPubMed

127.

Schwartz DJ, Langdon AE, Dantas G. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Med. 2020;12(1):82. https://doi.org/10.1186/s13073-020-00782-x.CrossRefPubMedPubMedCentral

128.

Geldart K, Borrero J, Kaznessis Y. Chloride-inducible expression vector for delivery of antimicrobial peptides targeting antibiotic-resistant Enterococcus faecium. Appl Environ Microbiol. 2015;81(11):3889–97. https://doi.org/10.1128/AEM.00227-15.CrossRefPubMedPubMedCentral

129.

Sulakvelitze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–59. https://doi.org/10.1128/AAC.45.3.649-659.2001.CrossRef

130.

Citorik RJ, Mimee M, Lu TK. Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol. 2014;19:59–69. https://doi.org/10.1016/j.mib.2014.05.022.CrossRefPubMed

131.

Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146–50. https://doi.org/10.1038/nbt.3043.CrossRefPubMedPubMedCentral

132.

Langdom A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39. https://doi.org/10.1186/s13073-016-0294-z.CrossRef

133.

Jumpertz R, Son Le D, Turnbauch B, Trinidad C, Bogardus C, Gordon J, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58–65. https://doi.org/10.3945/ajcn.110.010132.CrossRefPubMedPubMedCentral

Title: Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence
Authors: Natalia Vallianou
Maria Dalamaga
Theodora Stratigou
Irene Karampela
Christina Tsigalou
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Obesity
Obesity
Probiotics
Antibiotic
Respiratory Microbiota
Overweight
Published in: Current Obesity Reports / Issue 3/2021
Electronic ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-021-00438-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2021

The Bariatric-Metabolic Physician’s Role in Managing Clinically Severe Obesity

Endoscopic Procedures for Weight Loss

Social Isolation and Loneliness During the COVID-19 Pandemic: Impact on Weight

Adolescent and Childhood Obesity and Excess Morbidity and Mortality in Young Adulthood—a Systematic Review

The Impact of Restrictive and Non-restrictive Dietary Weight Loss Interventions on Neurobehavioral Factors Related to Body Weight Control: the Gaps and Challenges

Benefits of Low Carbohydrate Diets: a Settled Question or Still Controversial?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials